New Platform Matches Patients to Precision Oncology Trials
WEDNESDAY, Oct. 19, 2022 (HealthDay News) — A new open-source platform speeds matching of patients to precision medicine (PM) oncology trials, according to a study published online Oct. 6 in npj Precision Oncology.Harry Klein, Ph.D., from Dana-Farber…
Learn MoreComenzará en África un importante ensayo de TPOXX, el tratamiento para la viruela del simio
LUNES, 17 de octubre de 2022 (HealthDay News) — La capacidad de TPOXX de tratar a las personas infectadas con la viruela del simio se va a evaluar de forma directa en un nuevo ensayo en África Central, anunciaron las autoridades de salud de EE. UU. T…
Learn MoreMajor Trial of Monkeypox Treatment TPOXX to Launch in Africa
MONDAY, Oct. 17, 2022 (HealthDay News) — The ability of TPOXX to treat people infected with monkeypox is being directly tested in a new clinical trial in central Africa, U.S. health officials have announced.TPOXX — the antiviral drug tecovirimat — is…
Learn MorePeople With Disabilities Often Excluded From Clinical Trials
FRIDAY, Oct. 14, 2022 (HealthDay News) — People with disabilities are commonly excluded from clinical trials, according to a report published in the October issue of Health Affairs.Willyanne DeCormier Plosky, Ph.D., from Brigham and Women’s Hospital …
Learn MoreUn medicamento muestra potencial para la esclerodermia, una enfermedad autoinmune
LUNES, 10 de octubre de 2022 (HealthDay News) — Los investigadores informan un éxito temprano con el uso de un medicamento existente para la artritis reumatoide (AR), para tratar la esclerosis sistémica, una afección autoinmune rara pero potencialmen…
Learn MoreDrug Shows Promise Against Autoimmune Disease Scleroderma
MONDAY, Oct. 10, 2022 (HealthDay News) — Researchers report early success with using an existing rheumatoid arthritis (RA) drug to treat systemic sclerosis, a rare but potentially devastating autoimmune condition. The disease, a subset of scleroderma…
Learn MoreLos fármacos del Alzheimer se prueban sobre todo en blancos, y esto preocupa a pacientes y cuidadores negros
LUNES, 3 de octubre de 2022 (HealthDay News) — Larry Griner renunció a su trabajo en California y volvió a su hogar de la niñez, en Baltimore, hace casi cinco años, para poder cuidar a su madre, Norma.Norma había recibido un diagnóstico de enfermedad…
Learn MoreAlzheimer’s Meds Are Mostly Tested in Whites. That Worries Black Patients, Caregivers
MONDAY, Oct.3 2022 (HealthDay News) — Larry Griner resigned from his job in California and moved back to his childhood home in Baltimore nearly five years ago so he could care for his mother, Norma. She had been diagnosed with Alzheimer’s disease alm…
Learn MoreUn nuevo medicamento para el Alzheimer se muestra promisorio en un ensayo clínico en fase 3
MIÉRCOLES, 28 de septiembre de 2022 (HealthDay) — Eisai, una compañía farmacéutica japonesa, anunció el miércoles que su medicamento experimental lecanemab ayudó a ralentizar el deterioro del pensamiento en personas en las primeras etapas de la enfer…
Learn MoreNew Alzheimer’s Drug Shows Promise in Phase 3 Clinical Trial
WEDNESDAY, Sept. 28, 2022 (HealthDay) — Japanese drugmaker Eisai on Wednesday said its experimental drug lecanemab helped slow thinking declines among people in the early stages of Alzheimer’s disease. The findings from a phase 3 clinical trial have …
Learn More